{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:26:13Z","timestamp":1792801573899,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373041 and 82403637"],"award-info":[{"award-number":["82373041 and 82403637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373041 and 82403637"],"award-info":[{"award-number":["82373041 and 82403637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373041 and 82403637"],"award-info":[{"award-number":["82373041 and 82403637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Climing program of Harbin Medical University Cancer Hospital","award":["PDYS2024-01"],"award-info":[{"award-number":["PDYS2024-01"]}],"id":[{"id":"https:\/\/ror.org\/01f77gp95","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Climing program of Harbin Medical University Cancer Hospital","award":["PDYS2024-01"],"award-info":[{"award-number":["PDYS2024-01"]}],"id":[{"id":"https:\/\/ror.org\/01f77gp95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Brain metastasis significantly contributes to the failure of targeted therapy in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD). Reduced expression of RNA-binding motif protein 10 (RBM10) is associated with brain metastasis in these patients. However, the mechanism by which\n                      <jats:italic>RBM10<\/jats:italic>\n                      affects brain metastasis in EGFR-mutated LUAD remains unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An in vitro blood-brain barrier (BBB) model and brain metastasis-prone cell lines (BrM3) were established to confirm the brain metastatic potential of tumor cells following RBM10 knockdown. The roles of RBM10 and galactosylceramidase (GALC) in LUAD brain metastases were analyzed using cellular phenotypic assays and molecular biology techniques, including the combined analysis of Nanopore sequencing and CLIP-seq, minigene assays, and others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study demonstrates that RBM10 plays a vital role in inhibiting brain metastasis from EGFR-mutated LUAD by modulating sphingolipid metabolism. When RBM10 expression is low, GALC enters the nucleus to function. RBM10 deficiency inhibits exon skipping during GALC splicing, leading to upregulated GALC expression and increased sphingosine 1-phosphate (S1P) synthesis. S1P enhances BBB permeability, thereby promoting brain metastasis. Additionally, animal experiments show that the targeted agents Fingolimod (an S1P inhibitor) and RU-SKI-43 (a potential drug for RBM10 mutation) suppress the growth of brain metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study offers insights into the potential mechanisms of brain metastasis in LUAD and suggests a possible therapeutic target for further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03347-1","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T03:34:02Z","timestamp":1741664042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Gang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"3347_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1748-717X-6-23","volume":"6","author":"S Vill\u00e0","year":"2011","unstructured":"Vill\u00e0 S, Weber DC, Moretones C, Ma\u00f1es A, Combescure C, Jov\u00e9 J, et al. Validation of the new graded prognostic assessment scale for brain metastases: a multicenter prospective study. Radiat Oncol. 2011;6:23.","journal-title":"Radiat Oncol"},{"issue":"2","key":"3347_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","volume":"135","author":"M Ge","year":"2017","unstructured":"Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol. 2017;135(2):413\u20138.","journal-title":"J Neurooncol"},{"issue":"19","key":"3347_CR3","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.2015.64.2322","volume":"34","author":"T Kawaguchi","year":"2016","unstructured":"Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, et al. Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung Cancer study. J Clin Oncol. 2016;34(19):2247\u201357.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3347_CR4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41392-021-00773-3","volume":"6","author":"P Wang","year":"2021","unstructured":"Wang P, Li Y, Lv D, Yang L, Ding L, Zhou J, et al. Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib\/II efficacy and biomarker study. Signal Transduct Target Ther. 2021;6(1):374.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"3347_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.jtho.2021.05.019","volume":"16","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu H, Murakami H, Harada H, Shimizu J, Hayashi H, Daga H, et al. Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; West Japan oncology group 6911L. J Thorac Oncol. 2021;16(10):1745\u201352.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3347_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-21-0910","volume":"12","author":"AK Biswas","year":"2022","unstructured":"Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, et al. Targeting S100A9-ALDH1A1-Retinoic acid signaling to suppress brain relapse in EGFR-Mutant lung Cancer. Cancer Discov. 2022;12(4):1002\u201321.","journal-title":"Cancer Discov"},{"issue":"4","key":"3347_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s43018-021-00183-y","volume":"2","author":"GB Ferraro","year":"2021","unstructured":"Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Fatty acid synthesis is required for breast Cancer brain metastasis. Nat Cancer. 2021;2(4):414\u201328.","journal-title":"Nat Cancer"},{"issue":"7837","key":"3347_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41586-020-2969-2","volume":"588","author":"X Jin","year":"2020","unstructured":"Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, et al. A metastasis map of human cancer cell lines. Nature. 2020;588(7837):331\u20136.","journal-title":"Nature"},{"issue":"11","key":"3347_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/jnr.23873","volume":"94","author":"JS Won","year":"2016","unstructured":"Won JS, Singh AK, Singh I. Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe\u2019s disease. J Neurosci Res. 2016;94(11):990\u20131006.","journal-title":"J Neurosci Res"},{"key":"3347_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","volume":"688","author":"CR Gault","year":"2010","unstructured":"Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1\u201323.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"3347_CR11","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12035-019-01844-x","volume":"57","author":"S Nakagawa","year":"2020","unstructured":"Nakagawa S, Aruga J. Sphingosine 1-Phosphate signaling is involved in impaired Blood-Brain barrier function in ischemia-Reperfusion injury. Mol Neurobiol. 2020;57(3):1594\u2013606.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"3347_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.prp.2011.11.008","volume":"208","author":"J Du","year":"2012","unstructured":"Du J, Zeng C, Li Q, Chen B, Liu H, Huang X, et al. LPS and TNF-\u03b1 induce expression of sphingosine-1-phosphate receptor-2 in human microvascular endothelial cells. Pathol Res Pract. 2012;208(2):82\u20138.","journal-title":"Pathol Res Pract"},{"key":"3347_CR13","doi-asserted-by":"publisher","first-page":"19814","DOI":"10.1038\/srep19814","volume":"6","author":"R Wiltshire","year":"2016","unstructured":"Wiltshire R, Nelson V, Kho DT, Angel CE, O\u2019Carroll SJ, Graham ES. Regulation of human cerebro-microvascular endothelial baso-lateral adhesion and barrier function by S1P through dual involvement of S1P1 and S1P2 receptors. Sci Rep. 2016;6:19814.","journal-title":"Sci Rep"},{"issue":"4","key":"3347_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/dnares\/2.4.167","volume":"2","author":"T Nagase","year":"1995","unstructured":"Nagase T, Seki N, Tanaka A, Ishikawa K, Nomura N. Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1995;2(4):167\u201374.","journal-title":"DNA Res"},{"issue":"1","key":"3347_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/21655979.2021.1890382","volume":"12","author":"S Zheng","year":"2021","unstructured":"Zheng S, Wang X, Fu Y, Li B, Xu J, Wang H, et al. Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer. Bioengineered. 2021;12(1):791\u2013802.","journal-title":"Bioengineered"},{"issue":"1","key":"3347_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-021-00243-7","volume":"6","author":"F Zhang","year":"2022","unstructured":"Zhang F, Wang J, Xu Y, Cai S, Li T, Wang G, et al. Co-occurring genomic alterations and immunotherapy efficacy in NSCLC. NPJ Precis Oncol. 2022;6(1):4.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"3347_CR17","doi-asserted-by":"publisher","first-page":"20243","DOI":"10.1038\/s41598-020-76791-y","volume":"10","author":"Y Shang","year":"2020","unstructured":"Shang Y, Li X, Liu W, Shi X, Yuan S, Huo R, et al. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to Icotinib\/gefitinib. Sci Rep. 2020;10(1):20243.","journal-title":"Sci Rep"},{"issue":"5","key":"3347_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.molcel.2013.11.010","volume":"52","author":"EG Bechara","year":"2013","unstructured":"Bechara EG, Sebesty\u00e9n E, Bernardis I, Eyras E, Valc\u00e1rcel J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 2013;52(5):720\u201333.","journal-title":"Mol Cell"},{"issue":"5","key":"3347_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41388-019-1034-9","volume":"39","author":"JH Jung","year":"2020","unstructured":"Jung JH, Lee H, Cao B, Liao P, Zeng SX, Lu H. RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53. Oncogene. 2020;39(5):1031\u201340.","journal-title":"Oncogene"},{"issue":"1","key":"3347_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7150\/ijbs.63598","volume":"18","author":"Y Cao","year":"2022","unstructured":"Cao Y, Geng J, Wang X, Meng Q, Xu S, Lang Y, et al. RNA-binding motif protein 10 represses tumor progression through the Wnt\/\u03b2- Catenin pathway in lung adenocarcinoma. Int J Biol Sci. 2022;18(1):124\u201339.","journal-title":"Int J Biol Sci"},{"issue":"16","key":"3347_CR21","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.18632\/aging.102163","volume":"11","author":"F Zhou","year":"2019","unstructured":"Zhou F, Geng J, Xu S, Meng Q, Chen K, Liu F, et al. FAM83A signaling induces epithelial-mesenchymal transition by the PI3K\/AKT\/Snail pathway in NSCLC. Aging. 2019;11(16):6069\u201388.","journal-title":"Aging"},{"key":"3347_CR22","doi-asserted-by":"publisher","first-page":"1218267","DOI":"10.3389\/fnagi.2023.1218267","volume":"15","author":"XH Ji","year":"2023","unstructured":"Ji XH, Liu TT, Wei AH, Lei HP, Chen Y, Wu LN, et al. Suppression of HnRNP A1 binding to HK1 RNA leads to glycolytic dysfunction in Alzheimer\u2019s disease models. Front Aging Neurosci. 2023;15:1218267.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"3347_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, Strittmatter N, Yan Y, Wrigley GL, et al. Preclinical comparison of the Blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27(1):189\u2013201.","journal-title":"Clin Cancer Res"},{"key":"3347_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2018.08.015","volume":"436","author":"KM Kreitzburg","year":"2018","unstructured":"Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, et al. FTY720 enhances the anti-tumor activity of carboplatin and Tamoxifen in a patient-derived xenograft model of ovarian cancer. Cancer Lett. 2018;436:75\u201386.","journal-title":"Cancer Lett"},{"issue":"2","key":"3347_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR -Mutated advanced Non\u2013Small-Cell lung Cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"26","key":"3347_CR26","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","volume":"42","author":"CM Blakely","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor Receptor\u2013Mutated Non\u2013Small cell lung cancer: A phase II multicenter study. J Clin Oncol. 2024;42(26):3105\u201314.","journal-title":"J Clin Oncol"},{"issue":"48","key":"3347_CR27","doi-asserted-by":"publisher","first-page":"28995","DOI":"10.1074\/jbc.270.48.28995","volume":"270","author":"MS Carter","year":"1995","unstructured":"Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, et al. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem. 1995;270(48):28995\u20139003.","journal-title":"J Biol Chem"},{"issue":"1","key":"3347_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10585-010-9354-8","volume":"28","author":"T Seike","year":"2011","unstructured":"Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis. 2011;28(1):13\u201325.","journal-title":"Clin Exp Metastasis"},{"issue":"11","key":"3347_CR29","doi-asserted-by":"publisher","first-page":"E1450","DOI":"10.21037\/jtd.2016.11.11","volume":"8","author":"W Dai","year":"2016","unstructured":"Dai W, Zhu H, Chen G, Gu H, Gu Y, Sun X, et al. Orchestration of the crosstalk between astrocytes and cancer cells affects the treatment and prognosis of lung cancer sufferers with brain metastasis. J Thorac Dis. 2016;8(11):E1450\u20134.","journal-title":"J Thorac Dis"},{"issue":"2\u20133","key":"3347_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0014-5793(96)01050-2","volume":"395","author":"N Mizushima","year":"1996","unstructured":"Mizushima N, Koike R, Kohsaka H, Kushi Y, Handa S, Yagita H, et al. Ceramide induces apoptosis via CPP32 activation. FEBS Lett. 1996;395(2\u20133):267\u201371.","journal-title":"FEBS Lett"},{"issue":"52","key":"3347_CR31","doi-asserted-by":"publisher","first-page":"37355","DOI":"10.1074\/jbc.M113.494740","volume":"288","author":"HJ Abuhusain","year":"2013","unstructured":"Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, et al. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem. 2013;288(52):37355\u201364.","journal-title":"J Biol Chem"},{"issue":"4","key":"3347_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/ijms17040477","volume":"17","author":"JS Jung","year":"2016","unstructured":"Jung JS, Ahn YH, Moon BI, Kim HS. Exogenous C2 ceramide suppresses matrix metalloproteinase gene expression by inhibiting ROS production and MAPK signaling pathways in PMA-Stimulated human astroglioma cells. Int J Mol Sci. 2016;17(4):477.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3347_CR33","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1016\/S0021-9258(19)50708-6","volume":"267","author":"BM Buehrer","year":"1992","unstructured":"Buehrer BM, Bell RM. Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J Biol Chem. 1992;267(5):3154\u20139.","journal-title":"J Biol Chem"},{"issue":"6","key":"3347_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molmed.2015.03.006","volume":"21","author":"B Prager","year":"2015","unstructured":"Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med. 2015;21(6):354\u201363.","journal-title":"Trends Mol Med"},{"key":"3347_CR35","doi-asserted-by":"crossref","unstructured":"Selvam SP, Ogretmen B. Sphingosine kinase\/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance. Handb Exp Pharmacol. 2013;216:3\u201327.","DOI":"10.1007\/978-3-7091-1511-4_1"},{"issue":"4","key":"3347_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1124\/dmd.113.056176","volume":"42","author":"R Callaghan","year":"2014","unstructured":"Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014;42(4):623\u201331.","journal-title":"Drug Metab Dispos"},{"issue":"22","key":"3347_CR37","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","volume":"117","author":"A Salas","year":"2011","unstructured":"Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011;117(22):5941\u201352.","journal-title":"Blood"},{"issue":"3","key":"3347_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1541-7786.MCR-08-0156","volume":"7","author":"SE Schnitzer","year":"2009","unstructured":"Schnitzer SE, Weigert A, Zhou J, Br\u00fcne B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res. 2009;7(3):393\u2013401.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"3347_CR39","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/2159-8290.CD-20-1385","volume":"11","author":"G Foggetti","year":"2021","unstructured":"Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, et al. Genetic determinants of EGFR-Driven lung Cancer growth and therapeutic response in vivo. Cancer Discov. 2021;11(7):1736\u201353.","journal-title":"Cancer Discov"},{"key":"3347_CR40","doi-asserted-by":"crossref","unstructured":"Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT et al. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022;132(13).","DOI":"10.1172\/JCI145099"},{"key":"3347_CR41","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.ebiom.2020.103067","volume":"61","author":"S Zhang","year":"2020","unstructured":"Zhang S, Bao Y, Shen X, Pan Y, Sun Y, Xiao M, et al. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine. 2020;61:103067.","journal-title":"EBioMedicine"},{"issue":"11","key":"3347_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrm4063","volume":"16","author":"S Lykke-Andersen","year":"2015","unstructured":"Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16(11):665\u201377.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3347_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/CBM-170995","volume":"22","author":"DG Liu","year":"2018","unstructured":"Liu DG, Xue L, Li J, Yang Q, Peng JZ. Epithelial-mesenchymal transition and GALC expression of Circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer. Cancer Biomark. 2018;22(3):417\u201326.","journal-title":"Cancer Biomark"},{"issue":"22","key":"3347_CR44","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-19-3382","volume":"80","author":"M Belleri","year":"2020","unstructured":"Belleri M, Paganini G, Coltrini D, Ronca R, Zizioli D, Corsini M, et al. \u03b2-Galactosylceramidase promotes melanoma growth via modulation of ceramide metabolism. Cancer Res. 2020;80(22):5011\u201323.","journal-title":"Cancer Res"},{"key":"3347_CR45","doi-asserted-by":"crossref","unstructured":"Dowdy T, Zhang L, Celiku O, Movva S, Lita A, Ruiz-Rodado V et al. Sphingolipid pathway as a source of vulnerability in IDH1(mut) glioma. Cancers (Basel). 2020;12(10).","DOI":"10.3390\/cancers12102910"},{"issue":"10 Pt A","key":"3347_CR46","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1016\/j.bbamem.2015.07.013","volume":"1848","author":"KT Chang","year":"2015","unstructured":"Chang KT, Anishkin A, Patwardhan GA, Beverly LJ, Siskind LJ, Colombini M. Ceramide channels: destabilization by Bcl-xL and role in apoptosis. Biochim Biophys Acta. 2015;1848(10 Pt A):2374\u201384.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"3347_CR47","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/nar\/gks1327","volume":"41","author":"B Gu","year":"2013","unstructured":"Gu B, Eick D, Bensaude O. CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivo. Nucleic Acids Res. 2013;41(3):1591\u2013603.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3347_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13059-024-03242-6","volume":"25","author":"X Du","year":"2024","unstructured":"Du X, Qin W, Yang C, Dai L, San M, Xia Y, et al. RBM22 regulates RNA polymerase II 5\u2019 pausing, elongation rate, and termination by coordinating 7SK-P-TEFb complex and SPT5. Genome Biol. 2024;25(1):102.","journal-title":"Genome Biol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03347-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:35:35Z","timestamp":1741847735000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03347-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments involving the use of animals were approved by the Third Clinical Ethics Committee of Harbin Medical University. The use of human NSCLC and LCBM tissues and serums was obtained with the approval of the Third Clinical Ethics Committee of Harbin Medical University. All patients provided informed consent. The ethical project number is KY2023-68.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from each participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}